Lucid Diligence Brief: Syremis Therapeutics launches with $165M Series A in schizophrenia
Lucid Diligence Brief: Syremis Therapeutics launches with $165M Series A in…
Neuroscience Weekly News - September 17th 2025
🧠This Week in Neuroscience: RNAi Tau Therapy CTA, MS Patent Win, Generic…
Public Health Weekly News - September 5th 2025
Public Health Update: Early Alzheimer's Detection, Smartphone Use and…
Neuroscience Weekly News - June 4th 2025
🧠This Week in Neuroscience: Breakthroughs in MS, Schizophrenia, Gene Therapy…
How we helped a large-size Pharma prepare its sales and medical teams to beat a competitor launch of a new schizophrenia medication.
The Challenge: Gaining insights into competitor's new schizophrenia medication…